Suchergebnisse - (Person:"Lui, Grace")

PubPharm (20)

1

Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Chan, G. | Lui, G. | Wong, C. | +6

2

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes

enthalten in: JAMA network open | 2023

von Ma, B. | Yip, T. | Lui, G. | +8

3

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir

enthalten in: Gastroenterology | 2023

von Wong, G. | Hui, V. | Yip, T. | +3

4

Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis

enthalten in: The Journal of infection | 2022

von Lai, C. | Lui, G. | Wei, Y. | +9

CommentOn: J Infect. 2022 Jun;84(6):834-872. - PMID 35351541

5

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir

enthalten in: JAMA network open | 2022

von Wong, G. | Yip, T. | Lai, M. | +3

6

Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Yip, T. | Wong, V. | Tse, Y. | +7

7

Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B

enthalten in: Journal of hepatology | 2020

von Yip, T. | Wong, G. | Wong, V. | +6

CommentIn: J Hepatol. 2020 Sep;73(3):728-729. - PMID 32423630

8

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

enthalten in: Gastroenterology | 2020

von Yip, T. | Wong, V. | Chan, H. | +3

CommentIn: Gastroenterology. 2020 Jan;158(1):42-44. - PMID 31706943

9

Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma

enthalten in: Alimentary pharmacology & therapeutics | 2019

von Liang, L. | Wong, V. | Tse, Y. | +4

10

HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues

enthalten in: Journal of hepatology | 2019

von Yip, T. | Wong, G. | Chan, H. | +4